Hosted on MSN
First-in-human trial of CRISPR gene-editing therapy safely lowers cholesterol and triglycerides
In a 15-patient, Phase 1, first-in-human trial, a one-time CRISPR-Cas9 gene-editing therapy safely reduced LDL cholesterol and triglycerides in people with difficult-to-treat lipid disorders, ...
A version of this Priestley Medal address will be presented at the American Chemical Society Spring 2026 meeting ...
ZUG, Switzerland and BOSTON and SAN DIEGO and SHANGHAI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based ...
A major medical milestone took place in May 2025, when doctors at the Children’s Hospital of Philadelphia used CRISPR-based gene editing to treat a child with a rare genetic disorder. Unlike earlier ...
Scientists in China report removing HIV from human DNA using gene-editing technology. Experts say the findings are promising but still far from a confirmed cure.
In a Phase 1, first-in-human trial, a one-time infusion of an investigational CRISPR-Cas9 therapy targeting angiopoietin-like protein 3 (ANGPTL3) was safe and reduced LDL cholesterol by nearly 50% and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results